» Articles » PMID: 39330888

Diagnosis and Management of Neonatal Bacterial Sepsis: Current Challenges and Future Perspectives

Overview
Date 2024 Sep 27
PMID 39330888
Authors
Affiliations
Soon will be listed here.
Abstract

Sepsis remains the second cause of death among neonates after the pathological consequences of extreme prematurity. In this review we summarized knowledge about pathogens causing early-onset sepsis (EOS) and late-onset sepsis (LOS), the role of perinatal risk factors in determining the EOS risk, and the tools used to reduce unnecessary antibiotics. New molecular assays could improve the accuracy of standard blood cultures, providing the opportunity for a quick and sensitive tool. Different sepsis criteria and biomarkers are available to date, but further research is needed to guide the use of antibiotics according to these tools. Beyond the historical antibiotic regimens in EOS and LOS episodes, antibiotics should be based on the local flora and promptly modulated if specific pathogens are identified. The possibility of an antibiotic lock therapy for central venous catheters should be further investigated. In the near future, artificial intelligence could help us to personalize treatments and reduce the increasing trend of multidrug-resistant bacteria.

Citing Articles

16 S rRNA-based molecular identification of coagulase-negative Staphylococcus species in neonates with sepsis and their antibiotic resistance patterns in Ahvaz, Iran.

Malakian A, Dehghan S, Abbasi Montazeri E, Aramesh M, Dehdashtian M, Aletayeb S BMC Microbiol. 2025; 25(1):114.

PMID: 40033203 PMC: 11874690. DOI: 10.1186/s12866-025-03809-8.


Frequency and types of antibiotic usage in a referral neonatal intensive care unit, based on the world health organization classification (AwaRe).

Hematian F, Aletayeb S, Dehdashtian M, Aramesh M, Malakian A, Aletayeb M BMC Pediatr. 2025; 25(1):60.

PMID: 39856585 PMC: 11759425. DOI: 10.1186/s12887-025-05407-z.


Off-Label Use of Anakinra in Inflammatory Conditions in Neonates and Infants Up to 3 Months of Age: A Case Series and a Review of the Literature.

De Rose D, Campi F, Maddaloni C, Ronci S, Caoci S, Savarese I Paediatr Drugs. 2025; .

PMID: 39804459 DOI: 10.1007/s40272-024-00679-x.

References
1.
Stoll B, Puopolo K, Hansen N, Sanchez P, Bell E, Carlo W . Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of Escherichia coli, and the Need for Novel Prevention Strategies. JAMA Pediatr. 2020; 174(7):e200593. PMC: 7199167. DOI: 10.1001/jamapediatrics.2020.0593. View

2.
Hayes R, Hartnett J, Semova G, Murray C, Murphy K, Carroll L . Neonatal sepsis definitions from randomised clinical trials. Pediatr Res. 2021; 93(5):1141-1148. PMC: 10132965. DOI: 10.1038/s41390-021-01749-3. View

3.
Ehl S, Gering B, Bartmann P, Hogel J, Pohlandt F . C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics. 1997; 99(2):216-21. DOI: 10.1542/peds.99.2.216. View

4.
Nanduri S, Petit S, Smelser C, Apostol M, Alden N, Harrison L . Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance. JAMA Pediatr. 2019; 173(3):224-233. PMC: 6439883. DOI: 10.1001/jamapediatrics.2018.4826. View

5.
Curley A, Stanworth S, Willoughby K, Fustolo-Gunnink S, Venkatesh V, Hudson C . Randomized Trial of Platelet-Transfusion Thresholds in Neonates. N Engl J Med. 2018; 380(3):242-251. DOI: 10.1056/NEJMoa1807320. View